What is Fathom Pharma?
Fathom Pharma is a pharmaceutical company dedicated to combating the opioid crisis through the creation of novel, non-abusable pain therapeutics. The company's core focus lies in developing long-acting injectable pain medications designed for direct physician administration, thereby mitigating the risks associated with drug abuse. By prioritizing enhanced efficacy and reduced side effects, Fathom Pharma aims to redefine pain management solutions and establish itself as a leader in the healthcare sector, particularly within the pain therapeutics market.
How much funding has Fathom Pharma raised?
Fathom Pharma has raised a total of $47M across 1 funding round:
Series A
$47M
Series A (2026): $47M with participation from Chemistry VC, Sutter Hill Ventures, and Alexandria Venture Investments LLC Alexandria Venture Investments
Key Investors in Fathom Pharma
Chemistry VC
Chemistry VC is an early-stage venture capital firm specializing in seed and Series A investments in standout software companies, with a focus on fintech, infrastructure, developer tools, and work software. They aim to align their success with founders through active support and a lean team structure.
Sutter Hill Ventures
Sutter Hill Ventures is a venture capital firm based in Palo Alto, California, with extensive experience in financing technology-based startups and assisting entrepreneurs in building market-leading companies. They offer expertise in strategy, business development, and financing.
Alexandria Venture Investments LLC Alexandria Venture Investments
Alexandria Venture Investments LLC Alexandria Venture Investments operates within the Venture Capital & Private Equity industry, based in Hughesville, Maryland. Specific investment focus areas are not detailed.
What's next for Fathom Pharma?
The recent major strategic investment in Fathom Pharma signals a critical growth phase, likely enabling the company to accelerate its research and development pipeline, scale manufacturing capabilities, and expand its market reach. This enterprise-level backing suggests confidence from investors in Fathom Pharma's strategy to address the opioid crisis with innovative, physician-administered pain therapeutics. Future endeavors will likely concentrate on clinical trial progression, regulatory approvals, and strategic partnerships to bring their non-abusable pain solutions to patients.
See full Fathom Pharma company page
